PharmaEssentia
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel chec… Read more
PharmaEssentia (6446) - Total Liabilities
Latest total liabilities as of September 2025: NT$4.70 Billion TWD
Based on the latest financial reports, PharmaEssentia (6446) has total liabilities worth NT$4.70 Billion TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PharmaEssentia - Total Liabilities Trend (2010–2024)
This chart illustrates how PharmaEssentia's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PharmaEssentia Competitors by Total Liabilities
The table below lists competitors of PharmaEssentia ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Whitbread plc
PINK:WTBCF
|
USA | $6.82 Billion |
|
Direct Line Insurance Group PLC
PINK:DIISY
|
USA | $6.31 Billion |
|
Spirax-Sarco Engineering plc
PINK:SPXSF
|
USA | $1.44 Billion |
|
TXNM Energy, Inc.
NYSE:TXNM
|
USA | $8.50 Billion |
|
Compagnie Générale des Établissements Michelin Société en commandite par actions
PINK:MGDDF
|
USA | $16.94 Billion |
|
PB Fintech Limited
NSE:POLICYBZR
|
India | ₹11.65 Billion |
|
StandardAero, Inc.
NYSE:SARO
|
USA | $3.89 Billion |
|
Hiscox Ltd
PINK:HCXLY
|
USA | $8.53 Billion |
Liability Composition Analysis (2010–2024)
This chart breaks down PharmaEssentia's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PharmaEssentia's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PharmaEssentia (2010–2024)
The table below shows the annual total liabilities of PharmaEssentia from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-09-30 | NT$3.59 Billion | +8.18% |
| 2023-09-30 | NT$3.32 Billion | +4.07% |
| 2022-09-30 | NT$3.19 Billion | +63.85% |
| 2021-09-30 | NT$1.95 Billion | +20.87% |
| 2020-09-30 | NT$1.61 Billion | +128.79% |
| 2019-09-30 | NT$704.33 Million | +111.46% |
| 2018-09-30 | NT$333.08 Million | +57.34% |
| 2017-09-30 | NT$211.69 Million | -7.21% |
| 2016-09-30 | NT$228.15 Million | -35.01% |
| 2015-09-30 | NT$351.04 Million | +84.52% |
| 2014-09-30 | NT$190.25 Million | +143.90% |
| 2013-09-30 | NT$78.00 Million | -57.66% |
| 2012-09-30 | NT$184.22 Million | -45.09% |
| 2011-09-30 | NT$335.51 Million | +408.54% |
| 2010-09-30 | NT$65.97 Million | -- |